

# High Titer Recombinant Influenza Viruses for Vaccines and Gene Therapy

#### View U.S. Patent No. 8,475,806 in PDF format.

#### WARF: P03322US

Inventors: Yoshihiro Kawaoka

The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing an efficient technique and system for producing high titer influenza A virus in vertebrate cells in the absence of helper virus.

### **Overview**

Influenza is a major disease in humans that can be prevented by vaccination. Because new epidemic strains arise every year or two, the conventional influenza vaccine must be adapted almost every year, making efficient vaccine production a major objective of pharmaceutical companies.

## The Invention

A UW-Madison researcher has developed an efficient technique and system for producing high titer influenza A virus in vertebrate cells in the absence of helper virus. The technology takes advantage of a reverse genetics system created by Dr. Kawaoka that allows efficient production of influenza virus for vaccines and gene therapy applications (see WARF reference number P03252US). In the technology described here, the inventor developed a new set of plasmids for use with the reverse genetics system. The plasmids contain cDNAs from a high titer influenza virus isolate; the promoter for RNA polymerase I or RNA polymerase II; and the terminator sequence for RNA polymerase I. When these constructs are transfected into host cells, the cells consistently generate high yields of infectious influenza particles.

## **Applications**

- · Influenza vaccine production
- · Rapid production of attenuated live-virus vaccine during a suspected pandemic
- · Vaccine vectors for gene therapy
- · Viral mutagenesis studies

## **Key Benefits**

- · Greatly enhances influenza viruses as vaccine vectors
- Viruses can be engineered to express foreign proteins or immunogenic epitopes.

## Additional Information

#### **Related Technologies**

For more information on the inventor's reverse genetics system, see WARF reference number P03252US

We use cookies/bh this site to enhance your experience and improve our marketing efforts By continuing to browse without changing your browser settings to block or delete genome. cookies, you agree to the storing of cookies and related technologies on your device. See our privacy policy.

**Tech Fields** 





- Drug Delivery : Other drug delivery technologies
- Drug Discovery & Development : Drug production & design
- Therapeutics & Vaccines : Vaccines

For current licensing status, please contact Jennifer Gottwald at jennifer@warf.org or 608-960-9854

We use cookies on this site to enhance your experience and improve our marketing efforts. By continuing to browse without changing your browser settings to block or delete cookies, you agree to the storing of cookies and related technologies on your device. See our privacy policy

